Global Availability of high-quality pharmaceuticals

We master the complexity of global market entries

Build your portfolio worldwide with us!

We at AET strongly believe that our high-quality medicines should be available throughout the world. Whether living in a developed country or in an emerging market – all patients, irrespective of their origin or nationality, should have access to our affordable medicines making their therapies better and improving their quality of life. That´s why we always strive for a global market entry approach for our customers.
Thanks to our global research and development and regulatory affairs knowledge we have already obtained more than 15.000 marketing authorizations in over 80 markets worldwide. We succeed in mastering the complexity of country-specific regulatory requirements and maintain close contact to the relevant pharmaceutical authorities. In the meantime, our huge network of global marketing partners can focus on their important brand marketing and save time and money.

Our global licensing approach

Global availability of our high-quality pharmaceuticals: marketing authorizations in 80+ countries

15.000+

marketing authorizations worldwide

5000+

products worldwide

How we drive better availability of our high-quality pharmaceuticals throughout the world

Our success factors for your global market entry

15.000+

MAs obtained

in80+

countries worldwide

150+

marketing partners in five continents

global R&D and regulatory affairs knowledge

15.000+

MAs obtained

in80+

countries worldwide

150+

marketing partners in five continents

global R&D and regulatory affairs knowledge

close contact to pharmaceutical authorities worldwide

highly professional project management

globally oriented supply chain management

several US filings

close contact to pharmaceutical authorities worldwide

highly professional project management

globally orientated supply chain management

several US filings

We are best practice

Mastering the global launch of Rivaroxaban

AET has successfully prepared the complex global registration and launch process of the generic medicine Rivaroxaban, a therapeutically equivalent version of the originator product Xarelto®Rivaroxaban is an anticoagulant medication (blood thinner) used to treat and prevent blood clots. Studies have demonstrated the satisfactory quality of our product and its bioequivalence to the reference product. Our country scope covers all relevant Western European and CEE countries, APAC region, Latin America, Middle East as well as Africa. Until today, about 30 states have already granted approval for our product – submissions for over 60 further countries are under preparation or already done. 

Rivaroxaban will be manufactured at our own GMP approved, European production site in Cyprus, and (amongst others) marketed by our cooperation partner, one of the biggest generic marketing firms in the world. With this global market entry, we enable millions of patients worldwide access to a life- improving, high-quality treatment – also in emerging countries where GMP-compliance is not always a standard yet.  

We are happy to help, get in touch

Do not hesitate to get in touch for more information about our global market entry approach. Our experts are always available to help.